Erythropoietin alfa — Competitive Intelligence Brief

Erythropoietin alfa (Erythropoietin alfa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology.

phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology Biologic

Target snapshot

Erythropoietin alfa (Erythropoietin alfa) — Bio Sidus SA. Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erythropoietin alfa TARGET	Erythropoietin alfa	Bio Sidus SA	phase 3	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
recomon (Epoetin Beta)	recomon (Epoetin Beta)	JW Pharmaceutical	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
epoetin beta [NeoRecormon]	epoetin beta [NeoRecormon]	Hoffmann-La Roche	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
human recombinant erythropoietin	human recombinant erythropoietin	Seoul National University Bundang Hospital	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

1. Amgen · 4 drugs in this class
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
3. Hospital de Clinicas de Porto Alegre · 2 drugs in this class
4. Pfizer · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Chong Kun Dang Pharmaceutical · 2 drugs in this class
7. Barts & The London NHS Trust · 1 drug in this class
8. Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Biocad · 1 drug in this class